Kornimate/medical-research-clean huggingface dataset:
advancing health equity by integrating social-clinical models during pregnancy

Conditions: Cardiovascular Diseases; Obesity, Maternal; Diabetes

Summary: this study is being done to find out if online referrals to a food management program for women, infants, and children (wic) made by clinical teams will get more people to enroll in wic. women aged 18 or older who get healthcare at geisinger, are pregnant, and are eligible to be referred to the wic program will be recruited. these women need to consent to join this study. there are four groups in this study. group 1 will get usual care with details about wic from their clinical team. group 2 will be sent to wic by their clinical team. the study team may help the clinical team with the referrals. group 3 will get details about wic from their clinical team and a dietitian will talk to them about heart-healthy diets and food management. group 4 will be sent to wic by their clinical team or study team and a dietitian will talk to them about heart-healthy diets and food management. participants who talk with the dietitians will be sent kitchen utensils based on need. this study will last about 18 months and will have 240 total subjects joining at about 60 per month. each subject will be in the study for about 6 months. subjects will be asked to complete surveys at the start and end of the study. some subjects will also be asked about their experience in the study after they are done.


Eligibility criteria:
inclusion criteria: * english speaking * confirmed pregnancy * public insurance (medicaid) or no insurance * if no insurance, must meet income eligibility for wic * intent to deliver at a geisinger facility * able and willing to provide consent exclusion criteria: * pre-existing wic enrollment as a pregnant person * not eligible for wic * private insurance * unwilling to participate for up to 12 months
study with lu af20513 in patients with mild alzheimer's disease (ad) or mild cognitive impairment (mci) due to ad

Conditions: Alzheimer Disease

Summary: the purpose of this study is to study the effect of monthly dosing with a single dose of lu af20513, with and without booster vaccine, on antibody response.

cohort 1 encompasses 8 patients enrolled prior to the protocol amendment (pa) 1, dose regimen 1. cohort 2 includes patients enrolled under the pa and will consist of 20 patients, randomly assigned to two arms: * dose regimen 2: 10 patients who will receive one administration of booster vaccine 4 weeks prior to the first imp administration * dose regimen 3: 10 patients who will not receive a booster vaccine after the pa1, the study consists of the following periods: * screening period - up to 12 weeks * priming period: 28 weeks, monthly dosing with lu af20513 * maintenance period - 56 weeks, quarterly dosing with lu af20513 * follow-up period - 4 weeks

Eligibility criteria:
inclusion criteria: * the patient has a diagnosis of ad or mild cognitive impairment (mci) due to ad. * the patient has evidence of an abnormal amyloid and tau status, consistent with ad, by means of a positive csf test at screening * the patient is aged ≥50 and ≤85 years. if a woman, the patient must be post-menopausal. exclusion criteria: * the patient has participated in a clinical study where he/she has received passive or active anti-aβ immunotherapy or other active immunisation for the treatment of ad. * the patient has, in the investigator's opinion, evidence and/or history (clinically or on mri) of any clinically significant neurodegenerative disease, serious neurological disorder, other intracranial or systemic diseases or conditions resulting in a definite or probable diagnosis of major or mild neuro-cognitive disorder other than ad, per dsm-5® criteria. other in- and exclusion criteria may apply
comparison performance vigileo vs. continuous cco (vigilance) in patients with induced therapeutic hypothermia

Conditions: Cardiac Arrest; Hypothermia, Induced

Summary: patients resuscitated from a cardiac arrest undergo therapeutic hypothermia as a treatment option. measuring the cardiac output in these patients is sometimes important, but difficult, as these patients require an invasive device for measurement. recently, a non-invasive device based on pulse-contour analysis of the arterial pulse was developed (the vigileo). hypothermia changes the pulse contour, so the performance of the vigileo in patients with induced therapeutic hypothermia is not known. therefore we conduct this observational study in which the cardiac output of the patients is measured with the traditional method and the vigileo simultaneously.


Eligibility criteria:
inclusion criteria: * patients who survived a cardiac arrest and are treated with therapeutic hypothermia * pulmonary arterial catheter placed by treating physician exclusion criteria: * arterial catheter placement is contraindicated * aortic valve insufficiency (moderate to severe) * placement of intra-aortic balloon pump (iabp) or a lvad (left ventricular assist device)

Keywords: validation of cardiac output measurement in hypothermic patients
intelligent customer-driven solution for children and their parents undergoing day surgery

Conditions: Tonsillitis; Herniorrhaphies; Surgery; Children; Parents

Summary: this research aims to evaluate the effectiveness of web-based mobile intervention (icory -solution) developed to pediatric patients and their parents in the pathway of outpatient surgery treatment in pre-intra- and postoperative setting: (1) examine the effectiveness of the intervention on children's preoperative anxiety and fear, and postoperative pain (2) examine the effectiveness of the intervention on parental anxiety and satisfaction in children´s care path and (3) examine the experiences of the gamification in children in the intervention group.

children and their families are entitled to know what is going to happen to them before undergoing day surgery and information must be based on the child's age and understanding. it is important to help children to cope with any upcoming surgery because the more anxious and fear they are, the more pain they experience after the day surgery. digital gaming solutions could help families and children to be better oriented to the coming treatment. icory -solution is a digital pathway for children and family and it contains a virtual tour to hospital and distraction games for children. the information on the application is aligned with the patient's individual needs based on the type of surgery and requirements.

Eligibility criteria:
inclusion criteria: * age between 7-12 years old * is scheduled for an elective day surgery * is able to speak, and read in finnish * is accompanied by their parents (either mother or father or both) during the perioperative period * has access to smart phone/tablet (own or rent from the project) exclusion criteria: * cognitive and learning disabilities identified from the medical record * a chronic illness and/or pain that required special medical care
orthokeratology lens decentration with two designs of corneal refractive therapy™ lenses: a one-year prospective study

Conditions: Myopia Progression

Summary: background/objectives: to examine the trend of treatment zone (tz) decentration over 12 months of orthokeratology (ok) wear using two corneal refractive therapy (crt) lens designs: standard (std) and dual axis (da). methods: a prospective, randomized, longitudinal study was conducted at the optometry clinic of the complutense university of madrid. subjects were fitted with std or da designs in one of the eyes, randomly. refraction, uncorrected visual acuity (va) and corneal topography were performed at baseline, 1-night, 1-week, 1-, 3-, 6- and 12-month of lens wear. subjects requiring lens parameter adjustments or replacements after 3 months were excluded. decentration was measured by subtracting pre-ok from post-ok tangential curvature maps at each visit, with decentration distance and corneal optical tz measured using matlab. correlations between decentration and visual acuity (va) were also analyzed.


Eligibility criteria:
inclusion criteria: * age between 8 to 17 years old * myopia up -6.00 d exclusion criteria: * ocular diseases

Keywords: myopia; orthok
efficacy of seven-day combined rabeprazole plus levofloxacin plus augmentin for eradication of helicobacter pylori

Conditions: Helicobacter Pylori Infection

Summary: this prospective controlled randomized open-label clinical trial is designed to determine the eradication rate of 7-day levofloxacin, amoxicillin/clavulanate and rabeprazole regimen compared with 7-day standard triple therapy for adults infected with helicobacter pylori in eastern taiwan.

background: the resistance rate of helicobacter pylori (hp) to amoxicillin and metronidazole therapy is significantly higher in eastern taiwan as compared to national and worldwide rates. the high resistance rate in this territory justified a search for a better eradication regimen for hp infection. aim: to evaluate the efficacy and tolerability of a combination therapeutic regimen of levofloxacin, amoxicillin/clavulanate and rabeprazole (lacr) versus a conventional seven-day triple therapy with clarithromycin, amoxicillin and rabeprazole (car) for the eradication of hp infection. methods: we conducted a open-labeled, prospective, randomized, controlled study in a large tertiary referral hospital in eastern taiwan. hp-positive therapy-naïve patients with a positive clo test as proven by gastroscopy were recruited for potential random assignment to two 7-day treatment groups: lacr or car (control). the primary end point of this study was to evaluate the eradication rate of lacr regimen. hp eradication was assessed using the 13c-urea breath test or clo test performed at least 4 weeks after end of treatment. compliance and adverse effects with therapy were determined by phone call or outpatient clinic follow up. expected result: the seven-day lacr regimen evaluated in this study provided improved hp eradication efficacy when compared with the traditional seven-day triple therapy in eastern taiwan.

Eligibility criteria:
inclusion criteria: * patient proved with infection of h. pylori in gastric mucosa * patient with signed informed consent. exclusion criteria: * woman in breast feeding or pregnancy. * allergy or severe adverse effects to drugs used in study. * severe complications of peptic ulcer disease (like perforation or obstruction). * patients with history of cancer or failure of major organs.

Keywords: helicobacter pylori levofloxacin amoxicillin/clavulanate rabeprazole eastern taiwan
microtransplantation versus auto-sct in ≥pr multiple myeloma patients

Conditions: Microtransplantation; Autologous Stem Cell Transplantation; Multiple Myeloma in Relapse

Summary: comparison of the efficacy and safety of microtransplantation and autologous transplantation in the treatment of ≥pr multiple myeloma patients, 2-year pfs and os were also been observed. to identify the role of microtransplantation in the treatment of multiple myeloma.

ndmm patients induction therapy with 4 cycles pcd/pad regimen, achieve ≥pr, eligible for sct, were randomly divided into two arms. one arm receive microtransplantation, and the other accept auto-sct. comparison of the efficacy and safety of two arms, 2-year pfs and os were also been observed. clear the above program related hematopoietic recovery, remission rate, infection and recurrence rate, survival rate and the formation of micro inlay, minimal residual disease and gvhd, etc. to identify the role of microtransplantation in the treatment of multiple myeloma.

Eligibility criteria:
inclusion criteria: 1. diagnosis mm compliance with imwg diagnostic criteria(2014) 2. induction therapy with 4 cycles pcd/pad regimen, achieve ≥pr 3. kps ≥60，ecog≤2 4）age 18-65，eligible for sct 5）heart function \ 50% - exclusion criteria: 1. kps\<60 2. allergy to bortezomib,epirubicin, or drug ingredients 3. severe hepatitis and organ dysfunction: a serious infection has not been controlled; cardiac ejection fraction \ 3mg/dl, severe abnormal results of liver function test (ast is greater than 3 times the upper limit), severe renal injury; central nervous system disorders, uncontrolled mental illness 4. with more than 2 bortezomib associated with peripheral neuropathy or neuralgia patients 5. patients with active stage of the herpes zoster 6. women in pregnancy or lactation 7. mm with al or em plasma cell tumor 8. the patient refused to accept the above treatment and signature 9. donor does not meet the requirements: including hiv positive, active hepatitis b, bone marrow disease, donor refused to provide hematopoietic stem cells and do not agree to sign. 10. epirubicin / other anthracyclines previously accumulated more than 240mg/m2 -

Keywords: microtransplantation multiple myeloma
efficiency of a tight monitoring by a nurse practitioner of rheumatoid arthritis (ra) patients in remission

Conditions: Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) is a progressive disease that affects mainly small and medium joints and, in the absence of appropriate background therapy, leads to progressive joint destruction, functional, psychological, social and occupational repercussions. several biomedicine treat this pathology, including rituximab (rtx). it is recommended to evaluate the therapeutic response to rtx and re-administer it from the 24th week when the goal of remission has not been achieved. however, the optimal modality for reprocessing remains to be determined. to this end, different approaches have been explored, such as lymphocyte typing or ultrasound monitoring. the pace of these examinations, however, remains wide and their cost is not negligible. this is why we propose here to explore the track of a tight follow-up nurse das28. the hypothesis is that a tight nursing follow-up can detect the symptomatic recovery earlier than the current medical follow-up. the hypothesis is that a tight nursing follow-up can detect the symptomatic recovery earlier than the current medical follow-up


Eligibility criteria:
inclusion criteria: * male or female (age 18 or older) * rheumatoid arthritis fulfilling the acr/eular 2010 criteria * patient to whom the rheumatologist prescribed a treatment with rituximab or who received a treatment with rituximab in the last 6 months * patients with active rheumatoid arthritis prior to treatment with rituximab (das 28 crp\>2.7) * patient with a das 28 crp of less than 2.7 at 6 months from the last administration of rituximab exclusion criteria: * patient not responding to the last treatment with rituximab (das28 crp\> 2.7 at 6 months) * patient under the age of 18 * patient with chronic pain due to another pathology than rheumatoid arthritis, which may interfere with the assessment * patient with a contraindication to treatment with rituximab * woman of childbearing age not taking effective contraception * pregnant or nursing woman

Keywords: rituximab tight monitoring
effect of acupuncture for qol in gastric cancer patients undergoing adjuvant chemotherapy: a pilot study

Conditions: Stomach Neoplasms

Summary: this is a pilot study evaluating the efficacy of acupuncture on quality of life in gastric cancer patients undergoing postoperative adjuvant chemotherapy. enrolled participates will randomly receive high-dose acupuncture, low-dose acupuncture or none-acupuncture during the first 3 cycles of adjuvant chemotherapy after resection.


Eligibility criteria:
inclusion criteria: * 1.pathologically diagnosed with gastric cancer or esophagogastric junction cancer after r0 resection and d2 lymph node dissection; * 2.pathological stage ii or stage iii； * 3.without tumor recurrence confirmed by image examination; * 4.no chemotherapy after surgery, planning to accept at least 3 cycles of adjuvant chemotherapy; * 5.age:18\~75 years old； * 6.ecog score≤ 2； * 7. normal organs function, including: 7.1 bone marrow function: absolute neutrophil count (anc)≥1.5×10e9/l, platelet (plt)≥100×10e9/l,hemoglobin (hb)≥90g/l; 7.2 kidney function: serum creatinine (scr)≤1.5mg/dl(133μmol/l), or creatinine clearance rate (ccr)≥60ml/min； 7.3 liver function: total bilirubin (tb)≤1.5×upper limit of normal value (uln), alanine transaminase (alt)≤2.5×uln, aspartate transaminase (ast)≤2.5×uln； * 8. can understand the study well and finish the questionnaires in this study; * 9. with the written informed consent. exclusion criteria: * 1. can not finish the baseline assessment; * 2. needle phobia; * 3. currently diagnosed with psychiatric disorder (e.g., severe depression, obsessive-compulsive disorder, or schizophrenia); * 4. history of autoimmune diseases, hematological diseases or organ transplantation, or long term use of hormones or immunosuppressors; * 5. implanted with heart pacemaker; * 6. has accepted neoadjuvant radiotherapy before surgery; * 7. planning to accept adjuvant radiotherapy after surgery; * 8. with active infection; * 9. acupuncture treatment within the previous 6 weeks; * 10.pregnant or lactating women.

Keywords: gastric cancer acupuncture quality of life adjuvant chemotherapy
a phase 2a study of tas5315 in patients with chronic spontaneous urticaria

Conditions: Chronic Spontaneous Urticaria

Summary: the purpose of this study is to evaluate the efficacy and safety of tas5315 in chronic spontaneous urticaria patients with an inadequate response to h1-antihistamines

the main purpose of this study is to assess the efficacy of tas5315 in chronic spontaneous urticaria patients with an inadequate response to h1-antihistamines compared with placebo as measured by the change from baseline in weekly urticaria activity score (uas7) at week 12

Eligibility criteria:
key inclusion criteria: * aged 18 to 75 years * diagnosis of chronic spontaneous urticaria (csu) * presence of itch and hives for at least 6 consecutive weeks prior to screening in spite of use of non-sedating h1-antihistamines for csu * uas7 score ≥ 16 and hss7 score ≥ 8 during 7 days prior to study entry * in-clinic uas ≥ 4 on study entry * willing and able to complete and participate daily for the duration of the study key exclusion criteria * diseases other than csu with symptoms of urticaria or angioedema, including urticarial vasculitis, erythema multiforme, mastocytosis, or hereditary or acquired angioedema * atopic dermatitis, psoriasis, ichthyosis, or other skin disease associated with chronic itching * bleeding diathesis * uncontrolled hypertension disease states * treatment with omalizumab or other humanized anti-human ige monoclonal antibody therapies used to treat csu within 4 months prior to screening * nonresponse to omalizumab or other humanized anti-human ige monoclonal antibody therapies * have been treated with other bruton's tyrosine kinase inhibitors * pregnant or lactating women
the association of marital status with kidney cancer surgery morbidity

Conditions: Marriage; Kidney Neoplasms; Surgery-Complications; Cohort Studies

Summary: retrospective cohort study

data source and study cohort: we conducted a retrospective cohort study using the premier healthcare database (phd, premier inc., charlotte, nc), an extensive, us hospital-based, all-payer database representing approximately 20% of annual united states inpatient discharges at community and academic centers. the international classification of diseases, ninth revision (icd-9), and tenth revision (icd-10) procedure codes were used to identify patients who had undergone elective kidney cancer surgery between the 15 years of study from 2003 to 2017. the cohort was then restricted based on appropriate icd-9 and icd-10 diagnosis codes to ensure that surgery was performed for a kidney mass. the study cohort was also limited to adult patients (age \>= 18 years), "elective" cases based on administrative codes, as well as surgery on hospital day zero or one to minimize outlier patients who could skew the surgical outcomes. outcomes: the primary outcome of this study was the 90-day complication rate. complication rates were based on the clavien-dindo classification of surgical complications and divided into four categories: no complications, minor complications (clavien grades 1, 2), and non-fatal major complications (clavien grades 3, 4), and mortality (clavien grade 5). clinical systems also categorized complications (bleeding, cardiac, endocrine, gastrointestinal, infection, neurology, pulmonary, renal, soft tissue, urologic, venous thromboembolism) using health care cost and utilization project clinical classification software level ii or iii designations; of note, the category for "surgical" complications was excluded given that all complications captured in this analysis are considered surgical complications. secondary outcomes included patient disposition, length of hospital stay, and readmission rate.

Eligibility criteria:
inclusion criteria: 1. surgery was performed for a kidney mass. 2. age \>= 18 years 3. "elective" cases 4. surgery was performed on the day0 or day1 after administration. exclusion criteria: 1. icd codes are not available. 2. missing value of the primary outcomes and exposure.

Keywords: marital status kidney cancer surgery surgical morbidity retrospective cohort study